国家医保局连开座谈会释放哪些新信号

Core Viewpoint - The article emphasizes the importance of implementing a comprehensive value assessment for innovative drugs and medical devices as a new policy tool under the "Measures to Support the High-Quality Development of Innovative Drugs" [1] Group 1: Policy Implementation - The National Healthcare Security Administration (NHSA) held a seminar focusing on the comprehensive value assessment of innovative drugs and devices, indicating a shift towards evaluating real-world effectiveness rather than solely relying on laboratory data [1] - Future value-based purchasing in healthcare will prioritize real-world data to enhance the effectiveness of insurance coverage decisions [1][2] Group 2: Research Directions - The research will focus on two main areas: comprehensive value assessment for basic medical insurance drug catalog management and for commercial health insurance innovative drug catalog management [2] - Specific topics include evaluating drugs not yet on the market within certain regions, proposed new inclusions in the catalog, and mechanisms for drug exit from the catalog [2] Group 3: Evaluation Framework - A systematic and comprehensive evaluation framework is needed to assess the value of medical products, addressing questions like "where to allocate funds" and "is the spending worthwhile" [2] - The evaluation process will occur in three stages: pre-market assessment, post-market but pre-insurance assessment, and post-insurance entry re-evaluation [3] Group 4: Expert Insights - Experts believe that the establishment of a comprehensive value assessment system will help avoid competitive internalization among innovative drugs and guide the rational allocation of medical resources [4] - The NHSA's initiative is seen as a significant step away from merely reducing drug prices to a more structured approach in determining insurance payment standards for innovative drugs [4]